MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Levels of ferritinemia in Parkinson’s disease patients who underwent Covid-19

    B. Amonov, R. Matmurodov, B. Muminov (Tashkent, Uzbekistan)

    Objective: Comparison of serum IL-6 levels in Parkinson's disease (PD) patients with and without Сovid-19. Background: In the scientific literature, there is information about the…
  • 2024 International Congress

    Effects of Osteopathic Manipulative Treatment (OMT) on Lower Extremity Muscle Characteristics in Parkinson’s Disease (PD) Patients

    R. Radigan, A. Finkelstein, M. Mehra, P. Bhushan, T. Lombardo, S. Yao (Old Westbury, USA)

    Objective: To define the mechanism of Osteopathic Manipulative Treatment (OMT) in decreasing symptomology and improving gait in Parkinson’s Disease (PD) patients. Background: A key symptom…
  • 2024 International Congress

    Investigating Interrater Reliability of the Unified Huntington’s Disease Rating Scale Motor Component Between Learner and Experienced Rater

    M. Janz, W. Adams, A. Key, R. Zschiegner, D. Burks, K. Shannon, J. Paulsen (Madison, USA)

    Objective: The aim of this project is to explore the interrater reliability of the standardized motor exam of the Unified Huntington’s Disease Rating Scale (UHDRS)…
  • 2024 International Congress

    Botulinum Toxin A Usage in Movement Disorder Division: A Retrospective Chart Review

    S. Shaikh, R. Figari Jordan (Charlottesville, USA)

    Objective: To evaluate the cost-effectiveness of Botulinum Toxin A in our movement disorder division. Background: Botulinum Toxin A is an FDA-approved treatment for various medical…
  • 2024 International Congress

    Patient and Caregiver Experiences with Tardive Dyskinesia: Emotions, Challenges, and Unmet Needs in the Patient Journey

    A. Peyser Levin, E. Kinjo, R. Ribalov, N. Chaijale, A. Yaari (Tel Aviv, Israel)

    Objective: To describe the emotional journey from symptom onset to current state and identify challenges and unmet needs of participants living with tardive dyskinesia (TD)…
  • 2024 International Congress

    Triple threat: A rare case of a patient with 3 co-existent autoimmune antibodies causing autonomic and movement disorder

    YK. Kim, KC. Colletta (Maywood, USA)

    Objective: We describe a unique case of a patient with a constellation of movement and autonomic abnormalities. Serum paraneoplastic/autoimmune testing was positive for 3 separate…
  • 2024 International Congress

    Role of the Alpha-synuclein Seed Amplification Assay in Parkinson’s Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson’s Disease

    E. Tharp, J. Martinez-Lemus, J. Suescun, C. Adams, M. Shahnawaz, T. Ellmore, M. Schiess (Houston, USA)

    Objective: Report a patient with Multiple System Atrophy (MSA) misdiagnosed as Parkinson’s disease (PD) and enrolled in a clinical trial for PD treatment with Mesenchymal…
  • 2024 International Congress

    Lyme disease presenting as a rapidly progressive MSA-C look alike

    L. Zünd-Hofer, F. Brugger (Sankt Gallen, Switzerland)

    Objective: We report two cases of encephalomyelitis due to Lyme disease with cerebellar ataxia and autonomic symptoms, which presented with a rapidly progressive MSA-like phenotype.…
  • 2024 International Congress

    Clinical and neuroimaging factors associated with survival in Progressive Supranuclear Palsy

    G. Martí-Andrés, E. Prieto-Azcarate, CA. Espinoza-Vinces, L. van Bommel, S. Meles, M. Riverol, KL. Leenders, J. Arbizu, MR. Luquin-Puido (Pamplona, Spain)

    Objective: To assess clinical and neuroimaging factors associated with survival in a cohort of patients with a final clinical diagnosis of Progressive Supranuclear Palsy (PSP)…
  • 2024 International Congress

    Metabolic Progressive Subtypes in Progressive Supranuclear Palsy

    H. Wang (Hangzhou, China)

    Objective: To investigate disease-specific spatiotemporal progression in Progressive supranuclear palsy (PSP) patients using 18F-fluorodeoxyglucose (FDG) PET and the Subtype and Stage Inference (SuStaIn) algorithm, to…
  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley